Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations.

Viruses

Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA 30307, USA.

Published: May 2022

Long-acting (LA) anti-HIV regimens show promise for increasing dosing intervals and consequently, improving the patients' quality of life. The first FDA-approved LA therapy is Cabenuva, which comprises rilpivirine (a non-nucleoside reverse transcriptase inhibitor) and cabotegravir (integrase strand transfer inhibitor). Novel promising LA anti-HIV agents such as lenacapavir (a capsid-targeting antiviral) and islatravir (EFdA, a nucleoside reverse transcriptase translocation inhibitor) need to be explored as combination therapies. Therefore, we sought to determine whether combination of lenacapavir with islatravir, rilpivirine, or cabotegravir displayed synergy, additivity, or antagonism. We performed dose-response matrices of these drug combinations in an HIV-1 reporter cell line and subsequently analyzed the data with SynergyFinder Plus, which employs four major drug interaction models: highest single agent, Bliss independence, Loewe additivity, and zero interaction potency. Most of these models predict additive inhibition by the studied drug combinations This work highlights the importance of effective drug combinations in LA-regimens.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229705PMC
http://dx.doi.org/10.3390/v14061202DOI Listing

Publication Analysis

Top Keywords

drug combinations
12
reverse transcriptase
8
drug
5
drug interactions
4
interactions lenacapavir-based
4
lenacapavir-based long-acting
4
long-acting antiviral
4
combinations
4
antiviral combinations
4
combinations long-acting
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!